NICE to join GetReal Institute alongside nine key healthcare players

pharmafile | April 28, 2021 | News story | Research and Development EU, NICE, rwe 

NICE has announced it will join with nine other organisations to form the GetReal Institute, a not-for-profit multi-stakeholder enterprise, as a founding member.

Joining NICE, the following organisations have expressed their intention to sign up as founding members, pending finalisation and execution of membership agreements:

•             Clinical Practice Research Datalink (CPRD) (UK)

•             Eli Lilly and Company

•             Hoffmann-La Roche

•             GlaxoSmithKline

•             International Alliance of Patients’ Organizations (IAPO)

•             Janssen, Pharmaceutical Companies of Johnson & Johnson

•             National Institute for Health and Care Excellence (NICE) (UK)

•             Norwegian Medicines Agency (NoMA)

•             University Medical Center Utrecht (UMCU)

 The GetReal Institute has a mission to facilitate the adoption and implementation of real world evidence (RWE) in health care decision-making in Europe.

The Netherlands-based institute will act as a convening platform for key stakeholder groups in Europe, aiming to reach common understanding and prioritisation of critical opportunities and challenges in the generation, evaluation, and use of RWE.

Institute’s work will initially centre on the use of RWE to enhance understanding of the benefits, risks, and value of medicines and vaccines, with an elected Executive Board determining the Institute’s strategic and programmatic direction on behalf of the members.

Dr Felix Greaves, director of Science, Evidence and Analytics at NICE, said: “NICE is highly regarded around the globe and is seen as a world leader in health technology evaluation and the development of clinical guidelines.

“As well as looking at evidence generation for pharmaceuticals, the GetReal Institute will have an opportunity to expand its remit to incorporate medical technologies and digital health interventions. These are two areas where NICE shares a mutual interest of better data and research.

“Our role within the GetReal Institute will enhance our ability to work with like-minded organisations to tackle challenges in the area of real world evidence which need unified support in order to ensure the needs of patients are met in 2021 and beyond.”

Kat Jenkins

Related Content

AstraZeneca and MSD’s Lynparza receives NICE positive recommendation as a cancer maintenance treatment

UK-based pharmaceutical company AstraZeneca has announced that the National Institute for Health and Care Excellence …


GSK’s RSV vaccine approved in EU for older adults

GSK has announced that the European Commission (EC) has authorised Arexvy, the company’s respiratory syncytial …

NICE approves first treatment for obstructive HCM for NHS use

The National Institute for Health and Care Excellence (NICE) has announced that it has approved …

Latest content